Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04801550
Other study ID # 38RC20.370
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 22, 2021
Est. completion date December 17, 2021

Study information

Verified date January 2022
Source University Hospital, Grenoble
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The brain activity induced by a sensory stimulus and measured by magnetoencephalography will be compared before and after exposure to millimeter waves. We hypothesize that brain activity is modified after exposure to millimeter waves. The neuromodulatory effects of millimeter waves may lead to future development on therapeutic management in anxiety and pain.


Description:

Several studies showed clinical efficacy of millimeter waves in pain management, with no side-effects. However, its mechanism of action is still partly unknown. Preclinical studies showed that the use of millimeter waves near highly-innervated areas stimulates subcutaneous receptors, even at low power. To achieve safe millimeter wave stimulation, we will use a bracelet (Remedee Labs) emitting millimeter waves, that has been developped for human use. It complies with radiofrequency exposure regulation (CE-marked). This study aims to provide a better understanding of the mechanism by which millimeter waves interact with somatosensory system in brain. For this purpose, the analysis of brain activity will focus on somatosensory responses elicited by electrical stimulation of the right thumb. Subjects will complete two sessions during which the brain activity will be recorded by magnetoencephalography (MEG) before, during and after the use of a bracelet emitting millimeter waves. Magnetoencephalography is chosen for its good temporal resolution, its sensitivity in the low frequencies and its accuracy to locate neural sources when matching with an Magnetic Resonance (MR) Imagery. It will allow us to study the shape and the delay of the somatosensory response in primary somatosensory cortex (SI) and secondary somatosensory cortex (SII) cortical areas of the brain.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 17, 2021
Est. primary completion date December 17, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Healthy male voluntary subject, aged 18 to 40 inclusive. 2. Right-handed subject verified by the Edinburgh test. 3. Body mass index (BMI) between 18 and 25 kg/m2 inclusive. 4. Blood pressure and heart rate considered clinically normal by the investigators. 5. Having benefited from a medical examination before participating in the research. 6. Volunteer with a wrist circumference between 14.5 and 21 cm (wrist compatible with the size of the bracelet). 7. Adults, having expressed their consent to research, affiliated to a social security scheme and registered in the national file of people who lend themselves to biomedical research Exclusion Criteria: 1. Any history or presence of chronic disease. 2. Volunteer presenting chronic pain and / or headache. 3. Metal or silicon allergy. 4. Volunteer with a piercing or an implanted metallic material on the internal face of the right wrist. 5. Volunteer with a tattoo on the inside of the right wrist. 6. People with contraindications to MRI. 7. Taking treatment that could impact the physiological measurements recorded. 8. Consumption of analgesics or anti-inflammatory drugs during the week before each MEG examination. 9. Surgical intervention within the last 3 months. 10. Alcohol consumption within the last 24 hours, for each visit. 11. Achievement of a sporting effort within the last 24 hours, for each visit. 12. Volunteer with difficulties to be cooperative during the study in the opinion of the investigator (i.e.: language problem, poor mental development, etc.). 13. Volunteer in period of exclusion from another study. 14. Volunteer deprived of liberty by a judicial or administrative decision, subject to psychiatric treatment, or major subject subject to a legal protection measure (guardianship, guardianship and safeguard of justice) referred to in articles 1121-6 to 1121-8 of the French public health code. 15. Volunteer who would receive more than 4,500 euros in compensation as a result of his participation in other research involving the human person in the 12 months preceding this study. 16. Volunteer who cannot be contacted in case of emergency. 17. Volunteer who have already used an millimeter wave emitter before the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Millimeter waves local exposure
several blocks of somatosensory evoked potentials with or without Millimeter waves local exposure

Locations

Country Name City State
France Clinatec Cea/Chuga Grenoble

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Grenoble Commissariat A L'energie Atomique, Remedee SA

Country where clinical trial is conducted

France, 

References & Publications (3)

Fioravanti C, Kajal SD, Carboni M, Mazzetti C, Ziemann U, Braun C. Inhibition in the somatosensory system: An integrative neuropharmacological and neuroimaging approach. Neuroimage. 2019 Nov 15;202:116139. doi: 10.1016/j.neuroimage.2019.116139. Epub 2019 Aug 30. — View Citation

Radzievsky AA, Gordiienko OV, Alekseev S, Szabo I, Cowan A, Ziskin MC. Electromagnetic millimeter wave induced hypoalgesia: frequency dependence and involvement of endogenous opioids. Bioelectromagnetics. 2008 May;29(4):284-95. — View Citation

Rojavin MA, Ziskin MC. Electromagnetic millimeter waves increase the duration of anaesthesia caused by ketamine and chloral hydrate in mice. Int J Radiat Biol. 1997 Oct;72(4):475-80. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the somatosensory responses induced by the application of millimeter waves to the wrist Statistically significant change in the evoked somatosensory magnetic activity time course 4 hours
Secondary Variation of the sympathovagal balance following the application of millimeter waves Comparison of heart rate variability before and after application of millimeter waves 4 hours
Secondary Changes in resting brain activity during or after application of millimeter waves to the wrist Characterization of oscillatory brain activity by frequency bands (power maps) 4 hours
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1